CombiGene is currently conducting three gene therapy development projects and one peptide project: the pain program COZY consists of one peptide treatment and one gene therapy, which both are based on the same unique mechanism of action; the epilepsy project CG01 is developed for the treatment of drug-resistant focal epilepsy; and the CGT2 project for the treatment of lipodystrophy, a rare condition characterized by an abnormal distribution of fatty tissue in the body.
CombiGene now has a well-established international network within both the pharmaceutical industry and academia. The ambition is to form strategic partnerships for continued development and commercialization of the three projects which CombiGene is currently pursuing and to identify potential new projects in areas in which it may be possible to apply gene therapy.
In order to prepare CG01 to meet the needs of a global submission the remaining preclinical program will be expanded and, in some parts, complemented with additional studies in collaboration with Spark
CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 823282
CombiGene´s project CGT2 is supported by the Eurostars Programme. Project ID: 114714
Within the framework of the epilepsy project CG01, CombiGene has been collaborating with Lund University and the University of Copenhagen for many years. In recent years, CombiGene has also established collaboration regarding the preclinical development of the lipodystrophy project CGT2 with Stockholm University, University Medical Center Hamburg-Eppendorf and University of Michigan Medical School. The pain program COZY originates from academic research at Copenhagen University.